BIOGF Stock - Biocartis Group N.V.
Unlock GoAI Insights for BIOGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $57.48M | $48.27M | $43.13M | $37.44M |
| Gross Profit | $27.68M | $14.35M | $16.84M | $16.12M |
| Gross Margin | 48.2% | 29.7% | 39.1% | 43.0% |
| Operating Income | $-47,047,000 | $-62,645,000 | $-46,862,000 | $-55,602,000 |
| Net Income | $-65,381,000 | $-71,472,000 | $-62,934,000 | $-64,068,000 |
| Net Margin | -113.7% | -148.1% | -145.9% | -171.1% |
| EPS | $-1.08 | $-1.24 | $-1.11 | $-1.14 |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Visit WebsiteEarnings History & Surprises
BIOGFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Jun 13, 2024 | — | — | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.34 | — | — |
Q1 2023 | Feb 23, 2023 | — | $-0.58 | — | — |
Q4 2022 | Oct 20, 2022 | — | $-0.46 | — | — |
Q2 2022 | Apr 19, 2022 | — | $-0.62 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-0.62 | — | — |
Q2 2021 | May 14, 2021 | — | $-0.56 | — | — |
Q3 2020 | Sep 3, 2020 | — | $-0.56 | — | — |
Q1 2020 | Mar 5, 2020 | — | $-0.57 | — | — |
Q4 2019 | Nov 14, 2019 | — | $-0.57 | — | — |
Q1 2019 | Mar 1, 2019 | — | — | — | — |
Q4 2018 | Nov 15, 2018 | — | — | — | — |
Q2 2018 | Apr 26, 2018 | — | — | — | — |
Q4 2017 | Nov 28, 2017 | — | — | — | — |
Q2 2017 | Apr 27, 2017 | — | — | — | — |
Q3 2016 | Sep 6, 2016 | — | — | — | — |
Q2 2016 | May 12, 2016 | — | — | — | — |
Q4 2015 | Dec 11, 2015 | — | — | — | — |
Q2 2015 | Apr 17, 2015 | — | — | — | — |
Latest News
Frequently Asked Questions about BIOGF
What is BIOGF's current stock price?
What is the analyst price target for BIOGF?
What sector is Biocartis Group N.V. in?
What is BIOGF's market cap?
Does BIOGF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BIOGF for comparison